Abstract
The current situation in medicine and pharmacy still requires the time and effort of medicinal chemists, who must develop new synthetic approaches and create promising molecules that can turn into novel antimicrobials. Due to the problem of resistance to well-known antibiotics combined with the occurrence of new diseases that we observe, we can be sure that this research is going to be in demand. However, not always searching for a totally new molecule seems to be a good idea. The structural modification and hybridization of once efficient agents is also logical and actually has already provided us with many generations of antibiotics. Therefore, our scientific team has been working with fluoroquinolones with the aim of conducting docking studies, modifying them, and then studying the biological activity of the obtained compounds. In the first stage of the research, we conducted docking studies and then started to work on ciprofloxacin and norfloxacin, only modifying their C-7 position. The introduction of a 1,2,3-triazole moiety as a result of a convenient synthetic procedure led to new molecules for which moderate antimicrobial and antifungal activities were revealed. Furthermore, the C-3 position was modified with an arylsulfonyl moiety with parallel modifications of N-1 and C-7. For now, synthetic procedures have been developed for the similar transformation and biological activity of the obtained compounds that are under study.
Supplementary Materials
Poster presentation. The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ECMC2022-13145/s1.
Author Contributions
Conceptualization, S.M.K. and V.G.; methodology, L.S.; software, L.P.; validation, L.P. and N.F.; formal analysis, L.S.; investigation, H.H., L.P.; resources, S.M.K.; writing—original draft preparation, H.H.; writing—review and editing, S.M.K. and V.G.; visualization, L.P.; supervision, L.S., S.M.K. and V.G.; project administration, L.S.; funding acquisition, L.S. All authors have read and agreed to the published version of the manuscript.
Funding
Research was funded by the Ministry of Health of Ukraine from the state budget according to the topic ‘Molecular design and microbiological screening of innovative derivatives of fluoroquinolone antibiotics in order to combat resistant strains of microorganisms’ (state registration number: 0121U109239).
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).